
|Articles|August 1, 2011
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-08-01-2011
- Volume 23
- Issue 8
Improving API Synthesis
Author(s)Patricia Van Arnum
O-arylation and O-alkylation, a one-pot protein synthesis, a combined approach in continued and chemocatalysis, and green-chemistry applications are the target of some recent advances in API synthesis.
Advertisement
By Patricia Van Arnum
O-arylation and O-alkylation, a one-pot protein synthesis, a combined approach in continued and chemocatalysis, and green-chemistry applications are the target of some recent advances in API synthesis.
This article was also published in our US sister publication Pharmaceutical Technology and can be read
Articles in this issue
over 15 years ago
Understanding Fluidized-Bed Granulationover 15 years ago
Controlled Release from Porous Platformsover 15 years ago
Controlled Crystallization During Freeze-Dryingover 15 years ago
Movin' On Outover 15 years ago
The Many Varieties Of 'Emerging'over 15 years ago
Newsover 15 years ago
Managing Information Overloadover 15 years ago
The Importance Of Filter Testingover 15 years ago
Making A Mark In Emerging Marketsover 15 years ago
Croatia, Pharma and CorruptionAdvertisement
Related to this article

In October, FDA reorganized rare disease development around a fit-for-purpose framework and a new pathway for individualized gene editing. Regulators in Europe and the UK set out long-term plans for clinical trials, AI, and moving away from animal testing.

Clinical, manufacturing, safety, and commercial teams all lean on shared data. They need to agree on who publishes each data product, who can use it, and what evidence goes with it.

Structural modifications can improve peptide stability, solubility, and absorption to enable effective oral delivery.

The FDA approves VOCERYQ, the first DNA medicine, for RRP surgery reduction, raising plasmid, drug-device, and confirmatory trial manufacturing demands.

Continuous overall equipment effectiveness can be used to pinpoint hidden downtime and process bottlenecks in real time.

Subathra Ramamoorthy, Veranova, on how forced degradation and trace impurity profiling in potent APIs shape regulator-ready analytical methods.

The PharmTech team focused on its coverage of AAPS PharmSci 360 this week, conducting interviews with experts on a range of topics including formulation platforms, AI, amorphous solid dispersions, and animal studies.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
FDA’s New Inspection Playbook Counts Remote Assessments and MRA Reports Toward Facility Evaluations
2
Late-Phase Impurities Need Reference Standards: AAPS PharmSci 360 2026
3
RRP Accelerated Approval: What VOCERYQ Means for Manufacturing Teams
4
Who Answers for Your Data? Building a Life Sciences Data Mesh
5
